Cancer Drugs & Treatments Market Share, Growth and Forecasts to 2023: Hexa Reports

Hexa Reports

Market Research Reports and Insightful Company Profiles

Cancer Drugs & Treatments Market Data, Global Insights,

Share, Size, Emerging Trends, Growth, Analysis & Forecasts

To 2023

GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023.

GMR Data’s latest report 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’

explains just how this market will experience growth over the medium and long term.

The report also highlights forecast for the next 5 and 10 years, so that you and your company can make

specific long term plans. Don’t let your competitors get the head-start on you, order this report today.

Browse Detail Report With TOC @

http://www.hexareports.com/report/the-cancer-drugs-and-treatments-market/details

Have you seen the recent news on Cancer Drugs?

 Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year

 Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes

 EU approval for Bayer’s prostate cancer drug

 Sanofi ditches late-stage bone marrow cancer drug

The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the

largest and fastest growing areas for new drug development – can you afford not to be involved? Should

you and your company be capturing a greater market share?

Hexa Reports

Market Research Reports and Insightful Company Profiles

Essential facts examined in this report

1. Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for

Oncology.

2. Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.

3. Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side

effects.

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This

information is not available anywhere else. Find full details of these approved drugs alongside key

cancer...